Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance ...

UnitedHealth Group's pharmacy benefit manager, Optum Rx, said on Wednesday it would ease requirements to get insurance ...

The more we extend our horizon, the more likely it is that stocks will provide juicy returns. Investors can cash in by ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Treatments for autoimmune diseases and those in orphan markets are on the up and up, as are drugmakers’ first launches, ...

Amgen’s acquisition of Horizon Therapeutics in 2023 added several rare disease drugs, such as Tepezza, Krystexxa and Uplizna, to AMGN’s portfolio. Tepezza sales rose 3% year over year to $460 ...